Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia  by Tönshoff, Burkhard et al.
Kidney International, Vol. 45 (1994), pp. 1085—1092
Reduced hepatic growth hormone (GH) receptor gene
expression and increased plasma GH binding protein
in experimental uremia
BURKHARD TONSHOFF, STAFFAN EDEN, ECKART WEISER, BJORN CARLSSON,
lAIN C.A.F. ROBINSON, WERNER F. BLUM, and OTTO MEHLS
Division of Pediatric Nephrology, University Children's Hospital, Heidelberg, Germany; Department of Physiology, University of Goteborg,
Sweden; National Institute for Medical Research, London, England, United Kingdom; and University Children's Hospital,
Tubingen, Germany
Reduced hepatic growth hormone (GH) receptor gene expression and
increased plasma GH binding protein in experimental uremia. In uremia,
reduced longitudinal growth and decreased hepatic insulin-like growth
factor-I (IGF-1) secretion despite elevated GH serum levels point to an
insensitivity to the action of GH. The molecular basis that accounts for
this insensitivity could comprise decreased GH receptor expression in
the target organs for GH or binding of OH in the circulation to
substances that compete with the receptor. To address this hypothesis,
the abundance of hepatic GH receptor mRNA was measured by
solution hybridization RNase protection assay in uremic female Spra-
gue-Dawley rats, following two-stage 5/6 nephrectomy, and in pair-fed
and in ad libitum-fed sham-operated controls; rat OH binding protein
(GHBP) plasma concentration was measured by a sensitive direct RIA.
Uremia was associated with a 50% decrease of hepatic OH receptor
expression compared to pair-fed controls, which themselves showed a
25% reduction of hepatic GH receptor mRNA abundance when com-
pared to ad libitum-fed controls. Plasma GHBP levels in uremia were
markedly higher than in both control groups. Treatment with recombi-
nant human GH (rhGH) (10 lU/kg body wt per day s.c. for 10 days) led
to a comparable induction of IGF-I plasma levels and weight gain in
uremia and pair-fed controls, indicating that the insensitivity to OH in
uremia can be overcome by large rhGH doses. Subcutaneous rhGH
injections did not significantly alter the hepatic GH receptor transcript
abundance or plasma GHBP levels in any of the groups. Methylpred-
nisolone (6 mg/kg body wt per day given for 10 days) significantly
suppressed weight gain and food conversion ratio in all experimental
groups, accompanied by a 50% reduction of plasma GHBP, but without
a consistent effect on hepatic OH receptor mRNA abundance or
circulating IGF-I. This study demonstrates that experimental uremia in
rats leads to a decreased expression of hepatic GH receptor mRNA.
This decrease is partly due to a reduced nutritional intake but also
involves other as yet unidentified mechanisms. Circulating GHBP is
increased in the uremic state and could potentially compete for ligand
binding to the receptor. We hypothesize that both these alterations
contribute to GH insensitivity in uremia.
Growth in children with chronic renal failure as well as in rats
with experimental uremia is markedly reduced despite normal
or elevated growth hormone (GH) levels [1]. This discrepancy
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suggests an insensitivity to the action of GH at its target organs.
The molecular basis for this insensitivity to GH is not known. It
may involve, beside other possibilities, a decreased GH recep-
tor density or binding of Gil in the circulation to substances
that compete with the receptor. Indeed, a reduced number of
specific binding sites of ['251]GH on hepatic cell membranes
was found in experimental uremia, indicating reduced hepatic
GH receptor content [21. However, the experimental protocol
in that study did not include a pair-fed control group. As
reduced food intake is consistently observed in uremic animals,
it remains unclear whether reduced hepatic OH receptor den-
sity is a specific alteration in uremia that occurs independently
of the down-regulation of GH receptor abundance in malnutri-
tion [3].
The recent purification of a GH receptor from rabbit liver and
the subsequent cloning of GH receptor cDNAs in several
species [4—6] have provided a new tool to study the regulation of
the OH receptor by measuring its gene expression. Molecular
techniques for measuring OH receptor mRNA abundance may
be a more sensitive way of studying OH receptor regulation
than traditional binding methods. A close relation between the
OH receptor mRNA and the translated membrane receptor
concentration has been found in several circumstances [7, 8]. In
addition, a high-affinity OH-binding protein (GHBP) has been
described in different species, which corresponds to the extra-
cellular domain of the OH receptor. In humans and rabbits, it
has been suggested that the OHBP is produced by a proteolytic
release of the extracellular domain of the GH receptor [4, 9, 10].
Cloning studies in the rat and mouse have shown the GHBP in
these species to be a product of an alternative splicing event
during processing of the full-length OH receptor mRNA [11—
131. Since the liver is an abundant source of the truncated 1.3 kb
mRNA corresponding to GHBP, it is believed to be the primary
site of GHBP synthesis [7]. By complexing with circulating GH,
OHBP alters its clearance and distribution [14, 15]. Little is
known about the regulation of the receptor-related GHBP in
pathophysiological conditions. Under some circumstances,
OHBP reflects changes in OH receptor gene expression. For
example in the rat, hepatic GH receptors and plasma GHBP
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activity are both sexually dimorphic and can be up-regulated by
continuous infusion of exogenous GH [16—18].
The aim of the present study was to study the effect of
experimental uremia on GH receptor expression and circulating
GHBP in rats. To differentiate between the effects of uremia
and malnutrition, pair-fed and ad libitum-fed sham-operated
groups were also studied. Second, we investigated whether a
putative down-regulation of liver GH receptor expression in
uremia results in a decreased ability to synthezise insulin-like
growth factor-I (IGF-I) after stimulation with exogenous recom-
binant human (rh) OH, and whether the effects of rhGH on
IGF-I generation and body growth are accompanied by an
up-regulation of hepatic OH receptor. Third, we examined the
effects of methyiprednisolone (MP) on GH receptor mRNA
expression and the concentration of circulating GHBP, since
glucocorticoids in pharmacological doses have strong growth-
depressing effects both under clinical (for example, children
with renal transplants) and experimental conditions [19].
Methods
Experimental animals
Female Sprague-Dawley rats (Fa. Ivanovas, Kisslegg/Allgau,
Germany), weighing 70 to 80 g, were used for the experiments.
One week prior to the study, the animals were kept in single
cages at constant room temperature (24°C) and humidity (70%)
on a 12 hours on/12 hours off light cycle. The animals had free
access to food (Altromin C 1000 diet, Altromin Co., Lage,
Lippe, Germany) and deionized water. The diet contained:
13800 kJ/kg; 0.95% calcium; 0.8% phophorus, 500 lU/kg vita-
min D3; and 18% protein (wt/wt). The animals were randomized
to the experimental groups according to their body weight. The
animals were subjected to a two-stage subtotal nephrectomy
(NX) as described previously [20, 21]. Five days after 2/3
nephrectomy of the left kidney, the contralateral kidney was
removed and uremia resulted when the animals had a mean
body weight of 128 g. Control animals were sham operated
(renal decapsulation). Uremic animals and ad libitum-fed con-
trols had free access to food and water, whereas one of the
control groups was pair-fed to the uremic group as described
previously [20]. Pair-feeding started after the first stage opera-
tion. The duration of uremia in all experiments was 10 days.
Experimental protocol
In experiment 1 the three experimental groups were random-
ized with respect to the administration of either vehicle twice
daily s.c., or rhOH, 10 lU/kg body weight per day given twice
daily s.c. at 12-hour intervals for a period of 10 days. This dose
of rhGH stimulates growth maximally in the 5/6 nephrectomy
model [21]. RhOH (Oenotropin; 2.7 lU/mg, dissolved in saline)
was generously provided by Kabi Pharmacia (Stockholm, Swe-
den). In experiment 2 the three experimental groups were
randomized to the administration of either vehicle once daily
s.c., or MP, 6 mg/kg body weight per day given once daily s.c.
at 8 a.m. for a period of 10 days. This dosage of MP suppressed
growth maximally in a previous study using this 5/6 nephrec-
tomy rat model [21].
Tissue preparation
All measurements of body weight were performed in non-
fasted animals in the afternoon. The animals were killed by
aortic puncture at the end of the experiment. The tissue was
immediately frozen in liquid nitrogen and stored at —70°C.
Plasma was frozen at —20°C for subsequent analysis.
Biochemical measurements
Plasma urea was measured with a multichannel technicon
Autoanalyser (Technicon Instruments, Tarrytown, New York,
USA). Creatinine was determined by a kinetic method accord-
ing to Jaffe without deproteinization: the coefficient of variation
within the assay was <3%. Plasma IGF-I was measured after
acid-ethanol extraction as described previously [22] utilizing the
high-affinity antibody of Breier, Gallaher and Gluckman [231.
Residual IGFBP in the extract was blocked by adding 25 ng
recombinant IOF-Il (Kabi Pharmacia) per tube. Rat GHBP
plasma levels were measured by a sensitive direct RIA using an
antiserum raised against recombinant rat OHBP, as previously
described 124].
Solution hybridization
OH receptor mRNA was quantified by solution hybridization
RNase protection assay as previously described [25, 26]. In
brief, the tissue was homogenized in a buffer containing 1%
NaDodSO4, 20 mi Tris-HCI (pH 7.5), and 4 mM EDTA and
digested with proteinase-K (200 xglml) at 35°C for 35 minutes.
Total nucleic acids (TNA) were then extracted with phenol-
chloroform. The TNA samples were prepared from liver tissue
from individual rats.
TNA samples were hybridized at 70°C for 24 hours in 0.06
mM NaCI, 20 m Tris-HC1 (pH 7.5), 4 mM EDTA, 0.1%
NaDodSO4, 10 mvi dithiothreitol, and 25% formamide with a
35S-labeled OH receptor cRNA probe corresponding to part of
the extracellular domain of the rat OH receptor. The samples
were then treated with 40 pg RNase A and 2 jxg RNase T1 in the
presence of 100 g herring sperm DNA for 45 minutes at 37°C
in a volume of 1 ml. Protected probe was precipitated with 100
p1 trichloroacetic acid (6 M). The precipitate was collected on
glass-fiber filters (OF/C, Whatman International Ltd., Maid-
stone, UK) and counted in a scintillation counter. A tissue TNA
preparation, originally standardized against an in vitro tran-
scribed OH receptor mRNA, was used to generate a standard
curve. The standard curve was linear between 0.1 and 16 amol.
The DNA content of the samples was analyzed [27], and 10 to
45 tg DNA in samples were assayed. Within this range, the
hybridization signal parallelled the standard curve. In all as-
says, the lowest concentration of GH receptor mRNA mea-
sured was well above the lowest point of the standard curve.
Each TNA sample was analyzed in duplicate. The results are
expressed as the amount of GH receptor mRNA per DNA
(amol4tg). The coefficient of variation was 6% within and
between experiments.
GH receptor probe
A pT7T3 18 U vector carrying a 560-basepair BamHI frag-
ment [61 was linearized with EcoRI cleaving in the cloning box
of the vector, and labeled ([32P]UTP or [35S]UTP) cRNA was
generated with T3 polymerase (Promega, Madison, Wisconsin,
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Table 1. Growth, food intake, plasma chemistry, and plasma IGF-I concentration in uremic rats and pair-fed and ad libitum-fed sham-
operated controls, either treated with vehicle or rhGH (10 lU/kg body wt per day) (experiment 1)
Initial
weight Weight gain Food intake Food conversion
ratio g/g
Plasma creatinine Plasma urea Plma IGF-I
ng/mlmg/d!g
Uremia, vehicle
(N = 8) 92 7 16.1 3.3 119 6" 0.14 0.03 0.74 0.08 85.9 708 54b
rhGH (N = 8) 91 8 46.4 8.7" 138 l3 0.33 0.04" 0.79 0.04 103.0 4.2" 1075 114"
Pair-fed control
vehicle (N = 7) 92 7 28.3 3.5 121 5 0.23 0.03c 0.31 002b 29.9 2.5c 602 139"
rhGH (N = 7) 92 6 52.9 6.8" 139 14 0.38 O.O3' 0.33 0.03" 30.8 2.2" 1031 226"
Ad libitum-fed
controls
vehicle (N = 8) 92 7 35.0 5.9 150 11d 0.23 0.03" 0.31 005b 33.6 4.4" 1054 152""
rhGH (N = 7) 92 7 59.6 3.3 152 11d 0.39 002b 0.34 002b 33.6 3.6" 1184 410°
Statisticsa NS groups P < 0.001,
treatment
P<0.00l,
no interaction
groups P < 0.001,
treatment
P<0.00l,
no interaction
groups P < 0.001,
treatment
P<0.001,
no interaction
groups P < 0.001, groups P < 0.001,
treatment treatment
P<0.05, P<0.05,
no interaction significant
interaction
(P < 0.001)
groups P < 0.005,
treatment
P<0.001,
no interaction
Data are mean SD.
a Two-way ANOVA followed by all pairwise multiple comparison (Student-Newman-Keuls method). Superscript letters indicate significant
differences between groups. Values sharing common superscripts are not significantly different, while values without common superscripts are
significantly different. Significance level: 0.05.
Table 2. Growth, food intake, plasma chemistry, and plasma IGF-1 concentration in uremic rats and pair-fed and ad libitum-fed sham-
operated controls, either treated with vehicle or methylprednisolone (MP) (6 mg/kg body wt per day) (experiment 2)
Initial
weight Weight gain Food intake Food conversion
ratio g/g
Plasma creatinine Plasma urea Plasma IGF-I
ng/mIg mg/dl
Uremia, vehicle
(N = 8) 114 7 22.1 3.7 124 l1 0.18 0.04 0.77 o.lo 116.0 32.0 780 l66'
MP(N = 8) 113 6 7.9 3.5 118 5" 0.08 0.04 0.74 0.04a 142.8 17.2 832 257"
Pair-fed control
vehicle (N = 7) 112 6 26.7 3.6 125 12" 0.22 O.O4 0.32 0.08" 32.7 4.8a 615 1l8
MP(N 7) 112 6 12.3 5.9" 117 6b 0.10 005b 0.35 005b 47.0 l.9a 649 85ab
Ad libitum-fed
control
vehicle (N = 8) 113 6 31.8 5.2 140 9 0.23 0.03" 0.33 004b 35.3 6.1" 750 l2l
MP (N = 9) 112 6 15.0 5.Oa 132 11 0.11 004b 0.30 0.07" 47.1 6.4a 682 2l4aI
Statistics NS groups P < 0.001,
treatment
P < 0.001,
no interaction
groups P < 0.001,
treatment
P < 0.05,
no interaction
groups P < 0.05,
treatment
P < 0.001,
no interaction
groups P < 0.001, groups P < 0.002,
treatment NS, treatment
no interaction P < 0.001,
no interaction
groups P < 0.05,
treatment NS,
no interaction
Data are mean SD. Two way ANOVA followed by all pairwise multiple comparison (Student-Newman-Keuls method). Superscript letters
indicate significant differences between groups. Values sharing common superscripts are not significantly different, while values without common
superscripts are significantly different. Significance level: 0.05.
USA) under the conditions indicated by the manufacturer. This
probe does not distinguish between GH receptor and GHBP,
and therefore measures total Gil receptor and GHBP transcript
levels.
Statistics
Values are given as mean + SD, if not indicated otherwise.
For comparison between groups, a two way ANOVA was
performed, folilowed by all pairwise multiple comparison (Stu-
dent-Newman-Keuls method). P < 0.05 was accepted as being
statistically significant.
Results
The degree of uremia, estimated by plasma creatinine and
urea levels, was comparable in the two experiments and signif-
icantly higher than in controls (Tables 1 and 2). In vehicle-
treated animals, there was a stepwise reduction of weight gain
in uremia compared to pair-fed controls and in pair-fed controls
compared to ad-Iibitum-fed controls. The food conversion ratio
(weight gain per food intake) was low in uremic animals and
comparable in both control groups.
Quantification of hepatic GH receptor mRNA content by the
solution hybridization assay showed a stepwise reduction of
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Table 3. Quantification of hepatic GH receptor mRNA abundance by solution hybridization RNase protection assay, and plasma GHBP
concentrations, in uremic rats, and pair-fed and ad libitum-fed sham-operated controls
Experimental group
No. of
animals
GH receptor mRNA
amol/g DNA
No. of
animals GHBP ng/ml
Experiment 1
Uremia, vehicle 4 0.67 0.27a 8 8.9 6.l
rhGH 4 1.11 1.08k" 8 8.0 45a
Pair fed, vehicle 4 1.44 0.57" 7 5.1 1.7"
rhGH 4 1.50 0.39" 7 4.4 2.2
Adlibitum-fed, vehicle 3 1.91 0.42 8 4.0 2.2
rhGH 4 2.03 0.49c 7 3.9 2.5c
Statistics Groups P < 0.02,
rhGH treatment
NS, no interaction
Groups P < 0.01, rhGH
treatment NS, no
interaction
Experiment 2
Uremia, vehicle
MP
8
8
1.04 0.47a
1.17 0.81k
8
8
8.4 2.la
4.3 0.7"
Pair-fed, vehicle 8 1.63 0.74 7 5.4 2.3
MP 7 1.38 0.61a 7 2.7 06b
Adlibitum-fed, vehicle 9 2.21 2.18c 8 4.6 l.1
MP 8 2.00 0.81 9 34 16bc
Statistics Groups P < 0.05,
MP treatment NS,
no interaction
Groups P < 0.001, MP
treatment P < 0.001,
significant interaction
(P < 0.05)
Experiment I: Treatment either with vehicle or rhGH (10 lU/kg body weight per day s.c.) for 10 days. Experiment 2: Treatment either with
vehicle or methylprednisolone (MP) (6 mg/kg body weight per day s.c.) for 10 days. Data are given as mean SD.
P values are from two way ANOVA followed by all pairwise multiple comparison (Student-Newman-Keuls method). Superscript letters indicate
significant differences between groups. Values sharing common superscripts are not significantly different, while values without common
superscripts are significantly different. Significance level: 0.05.
GH receptor mRNA abundance in vehicle treated uremic
animals compared to pair-fed animals (significant in experiment
1) and in pair-fed animals compared to ad libitum-fed controls
(significant in experiment 2; Table 3). Uremic vehicle-treated
animals had a 36—53% decrease of GH receptor mRNA content
compared to pair-fed treated controls and a 53—65% decrease
compared to ad libitum-fed controls in experiment 1 and 2,
respectively. This difference indicates that the reduction of
hepatic GH receptor mRNA abundance in uremia is only
partially due to a reduced food intake, but partially caused by
alterations which are specific for the uremic milieu.
Mean GHBP plasma levels in vehicle-treated uremic animals
were elevated about twofold compared to pair-fed and ad
libitum-fed controls (Fig. 1, Table 3). Pair-fed animals had
slightly higher GHBP plasma levels than ad libitum-fed animals
(significant in experiment 1.) The absolute amount of GHBP
plasma levels in vehicle-treated animals as well as the percent-
age increase in the uremic group were well comparable between
experiments 1 and 2.
Plasma IGF-I levels (Tables 1 and 2) were similar in vehicle
treated pair-fed controls and uremic animals and lower than in
ad libitum-fed animals (significant in experiment 1), which
documents the known effect of malnutrition on circulating
IGF-I concentration [28].
Subcutaneous administration of rhGH over 10 days did not
significantly affect hepatic GH receptor mRNA content (Table
3) and circulating GHBP levels (Table 3, Fig. 1A) in any of the
groups. RhGH stimulated plasma IGF-I concentration in ure-
mia and pair-fed controls to a similar extent, whereas in ad
libitum-fed controls the effect on rhGH on plasma IGF-I was
only marginal (Table 1). Consistent with previously described
experiments [20], weight gain was relatively more pronounced
in rhGH-treated uremic rats (increase to 290% of vehicle-
treated rats) than in pair-fed controls (190%) and in ad libitum-
fed controls (170%; Table 1). This improvement in body growth
during rhGH was accompanied by an increased food conversion
ratio, which was again most pronounced in uremia, where the
ratio was normalized by rhGH in comparison to both control
groups. Food intake increased slightly, but not significantly
during rhGH treatment.
Subcutaneous MP injections, 6 mg/kg body weight per day
over a period of 10 days, did not significantly influence hepatic
GH receptor mRNA abundance in any of the experimental
groups (Table 3). In contrast, circulating GHBP plasma con-
centrations were markedly reduced by exogenous MP to a
comparable degree (decrease to 50% of vehicle-treated animals)
in uremic animals and pair-fed controls (Table 3, Fig. 1B). The
decrease in ad libitum-fed animals was less pronounced (74% of
vehicle-treated controls) and did not reach statistical signifi-
cance. MP did not consistently alter plasma IGF-I concentra-
tion in any of the groups (Table 2).
MP treatment led to a reduced weight gain in all groups, but
the largest effect was seen in the uremic animals (decrease to
36% of vehicle-treated animals) compared to pair-fed (46%) and
ad libitum-fed controls (47%; Table 2). This was paralleled by a
slight reduction in food intake and a more pronounced decrease
in the food conversion ratio as a reflection of the catabolic
action of glucocorticoids. The reduction of food conversion
ratio was comparable in the three experimental groups (de-
crease to 44 to 48% of vehicle-treated animals). The catabolic
action of MP was also reflected by higher plasma urea levels in
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Uremia Pair-fed Ad libitum-fed
controls controls
Fig. 1. Plasma GHBP concentration (mean s1M) in female uremic
rats and pair-fed or libitum-fed sham-operated controls, For number
of animals in each group see Tables 1 and 2. A. Rats either treated with
vehicle (U), or rhGH (; 10 lU/kg body wt per day s.c.). *significant
vs. vehicle- and rhGH-treated uremic rats, #significant vs. pair-fed
vehicle treated controls. B. Rats either treated with vehicle (U), or
methyiprednisolone (, 6mg/kg body wt per day s.c.). *sigrj1jcant vs.
vehicle-treated uremic animals, #signiflcant vs. vehicle-treated pair-fed
controls.
the MP treated rats, which reached significance in the uremic
animals.
Discussion
The present study demonstrates that experimental uremia is
characterized by a marked reduction in the abundance of
hepatic GH receptor mRNA (36—53% of pair-fed animals) and
by an even greater reduction (53—65%) compared to animals
with normal food intake. A similar decrease in hepatic GH
receptor mRNA in uremic, but not in pair-fed animals, has
recently been reported [291. This decrease in hepatic GH
receptor mRNA could be one of the molecular alterations that
accounts for the partial resistance to the growth-stimulating
effects of GH in uremia. The reduction of GH receptor mRNA
in uremia compared to pair-fed animals with the same nutri-
tional intake indicates that there is a specific effect of the uremic
metabolic milieu on hepatic Gil receptor mRNA content, which
exceeds the effect of a reduced food intake on hepatic OH
receptor expression. Indeed, the higher hepatic GH receptor
mRNA levels in ad libitum-fed animals compared to pair-fed
animals in our study indicate that hepatic GH receptor gene
expression is partly dependent on nutritional intake, which in
the uremic and pair-fed group was 80% of that of the ad
libitum-fed controls. This finding is consistent with previous
reports that reduced food intake is accompanied by a time-
dependent reduction of GH receptor mRNA in rat liver [30] and
by a reduced number of somatogenic (OH) receptors present on
liver cells [3, 31]. These alterations have also been implicated in
the resistance of liver to GH action under conditions of nutri-
tional deprivation.
The decreased abundance of liver GH receptor mRNA in
uremia could reflect a decrease in OH receptor gene transcrip-
tion, an inhibition of OH receptor mRNA processing, a de-
creased stability of GH receptor mRNA, or a combination
thereof. The hybridization assay used in the present study
measures the steady-state level of GH receptor transcripts and
provides no information on the mechanism involved in regulat-
ing the abundance of the transcripts.
At present, it is not known which mechanism peculiar to
uremia is responsible for the non-nutrition related decrease in
hepatic GH receptor mRNA abundance. Recent studies have
demonstrated that uremic rats exhibit decreased plasma levels
of albumin as a result of changes in the hepatocyte mRNA
*
steady-state level, which is caused by increased degradation. It
has been suggested that this increase in metabolism of albumin
mRNA may be due to increased levels of cellular ribonuclease
(RNase) [32]. Under normal conditions, the level of an endog-
enous cytoplasmatic ribonuclease inhibitor protein (RIP) is in
excess over the levels of RNases in the cytoplasm. Uremia
appears to perturb the normal balance of RNases to RIP, either
by changing the class abundance of RNase produced, or by
changing the expression of RIP, causing long-term changes in
albumin mRNA metabolism. Whether this mechanism is also
reponsible for reduced hepatic GH receptor mRNA content in
uremia should be addressed in future studies.
An additional new finding in the present study is the twofold
increase of GHBP plasma concentration in uremic animals. It
has been suggested that locally expressed and regulated GHBP
may interact directly with OH at the cellular level and affect the
balance between GH and the OH receptor. In vitro experiments
indicate that large amounts of GHBP decrease the binding of
GH to its membrane-anchored receptor and thereby inhibit OH
activity [33, 34]. Therefore, the functional consequences of
increased GHBP plasma values in uremia could be competition
with the GH receptor and decreased hormone availability to the
target cells. Theoretically, this increased binding of GH in
uremia could aggravate GH resistance in addition to reduced
GH receptor expression. Certainly, the mechanism of GHBP
production is different in humans compared to rodents.
Whereas in rats and mice, circulating GHBP is derived from an
alternatively spliced GHBP transcript [11, 12], it has been
suggested in humans and rabbits that the GHBP is produced by
a limited proteolytic cleavage of the receptor and the release of
the extracellular domain [9]. Nevertheless, the relevance of
elevated GHBP levels in the uremic rat model is underlined by
recent preliminary clinical data that immunoreactive GHBP
levels are also elevated in at least some children with end-stage
renal failure [35].
The mechanism of elevated GHBP levels in uremia remains
to be investigated. Theoretically, they could result from in-
creased hepatic production, from reduced renal filtration, or
from a combination of both. The solution hybridization tech-
nique used in the present study could not distinguish between
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the 4.0 kb mRNA encoding the Gil receptor and the 1.2 kb
mRNA encoding the GHBP. The most likely mechanism of
elevated GHBP plasma levels in uremic rats is a reduced
metabolic clearance rate of GHBP as a consequence of a
reduced functional renal mass. Because rat GHBP has a mo-
lecular weight of 33 to 42 kDa [16, 36], it can be assumed that it
is partially filtered by the kidney and metabolized by the
proximal tubule like other microproteins [37]. In this context it
is noteworthy that also other hormone binding proteins, such as
the IGF binding proteins IGFBP-l (MW 25 kDa), IGFBP-2 (34
kDa) and low molecular weight forms of IGFBP-3 (15 to 45
kDa), accumulate in uremia due to reduced renal clearance [38].
In the present study, chronic subcutaneous injection of rhGH
in rats did not significantly alter the GHBP plasma concentra-
tion in any of the experimental groups. This finding confirms the
general concept that the response of GHBP to exogenous GH is
dependent on the mode of administration: continuous GH
infusion, but not repeated GH injections increased plasma
GHBP activity in female hypophysectomized rats [39]. Inter-
estingly, the same differential regulation of serum GHBP by
continuous infusion versus daily injection of rhGH was recently
described in GH-deficient children [40]. Also, chronic injection
of rhGH did not influence the abundance of hepatic GH
receptor mRNA in our study, which is consistent with previous
findings in hypophysectomized rats [39].
The effects of GH on skeletal growth are partly mediated by
IGF-I [41]. Theoretically, resistance to the action of GH in the
liver should result in reduced expression of the IGF-I gene and
reduced circulating IGF-I peptide levels, which are mainly
derived from hepatic synthesis [42]. Indeed, the GH resistance
in fasting is reflected by reduced bioactive and immunoreactive
plasma IGF-I levels [29] as well as by a decline of IGF-I mRNA
content in rat liver [30]. This is in accordance with the findings
in our study that plasma IGF-I values in pair-fed animals, which
were comparable to the uremic group, were lower than in ad
libitum-fed animals. The lack of a difference in plasma IGF-I
levels between pair-fed and ad libitum-fed animals in experi-
ment 1 compared to experiment 2 could be due to a smaller
reduction in food intake in experiment 2. Previous studies also
did not find a difference in experimental uremia in plasma IGF-I
levels [20, 43] compared to a pair-fed group.
However, complexity to the interpretation of plasma IGF-I
levels is added by the observation of accumulation of IGF
binding proteins, mainly low molecular weight forms of
IGFBP-3, in uremia. This shifts the chemical equilibrium to
bound IGF and reduces the effective IGF bioactivity in uremic
plasma [38]. "Normal" immunoreactive IGF-I levels in uremia
may therefore be inadequately low, since under normal condi-
tions increased IGF-binding capacity would be immediately
saturated by IGF's produced in the liver. Indeed, analysis of
this complex system with a mathematical model indicates that
data from children with chronic renal failure (CRF) were
consistent with a reduced IGF-I secretion rate [44]. This
concept of low IGF secretion rate is in line with experimental
evidence for reduced hepatic Gil receptor gene expression in
the present study.
A previous report found no significant induction of hepatic
IGF-I mRNA content after one day of rhGH (2.6 lU/kg body
wt) in uremia and pair-fed animals compared to animals with
unlimited access to food [29]. In order to test whether high
doses of rhGH can overcome the decreased sensitivity to OH in
the uremic state in respect to hepatic IGF-I generation, we
treated animals with rhGH (10 lU/kg body wt) for 10 days.
Plasma IGF-I levels in uremic animals increased to an extent
comparable to in pair-fed animals in parallel with an increase in
body weight, indicating that GH resistance in uremia and in
mild malnutrition can readily be overcome by administration of
pharmacological doses of rhGH.
MP in pharmacological doses suppresses growth significantly
both under experimental [21] and clinical conditions [1]. Data
from this and earlier studies indicate that glucocorticoids dis-
play their catabolic action by a marked reduction in the food
conversion ratio, whereas the food intake was only moderately
decreased. The growth inhibiting effects of glucocorticoids are
multifactorial and involve reduced GH secretion, inhibition of
IGF-I bioactivity by production of inhibitors, alteration of IGF
binding activity, and direct effects on the skeletal tissue matrix
[19]. The concentration of circulating immunoreactive IGF-I
was not adversely affected by MP in the present study, in line
with clinical findings [45, 46]. The effect of pharmacological
doses of glucocorticoids on GH receptor expression and circu-
lating GH binding protein in vivo has not been studied previ-
ously. MP did not alter the abundance of total hepatic Gil
receptor mRNA in the present study. In vitro studies of binding
of labeled GH to primary hepatocyte cultures found that
dexamethasone induces the number of GH binding sites [47]. In
the present study, the circulating GHBP plasma levels were
significantly reduced by 50% both in uremic and pair-fed
animals, in contrast to the unchanged hepatic GH receptor
abundance. Since the 1.2 kb mRNA encoding the GHBP is a
distinct GH receptor gene product in the rat [11, 12], GH
receptor and GHBP mRNAs may not be coordinately regulated
in all circumstances. For example, a differential regulation of
the two transcripts has been found in different organs in the rat
[7] and during development [48].
In conclusion, the present study demonstrates a significant
reduction of hepatic OH receptor gene expression in experi-
mental uremia. Since the Gil receptor mRNA levels in uremia
are lower than those in the pair-fed group, this decrease cannot
be ascribed to food deprivation alone. In addition, increased
circulating GHBP concentration in experimental uremia could
inhibit binding of Gil to its receptor. Both alterations are likely
to contribute to the OH resistance in the uremic state. Unlike
other OH insensitivity syndromes, such as Laron syndrome
[49] and small stature of African pygmies [50], stimulation with
high doses of exogenous rhGH resulted in significant increases
of circulating IGF-I concentration and improved body growth.
This indicates that the resistance to the action of GH is only
partial and can be overcome by high exogenous Gil doses,
consistent with clinical observations both in children and adults
with CRF [51—58].
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